Literature DB >> 22528487

1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics.

Miroslava Cuperlovic-Culf1, Dean Ferguson, Adrian Culf, Pier Morin, Mohamed Touaibia.   

Abstract

Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by unpredictable clinical behaviors that suggest distinct molecular subtypes. With the tumor metabolic phenotype being one of the hallmarks of cancer, we have set upon to investigate whether GBMs show differences in their metabolic profiles. (1)H NMR analysis was performed on metabolite extracts from a selection of nine glioblastoma cell lines. Analysis was performed directly on spectral data and on relative concentrations of metabolites obtained from spectra using a multivariate regression method developed in this work. Both qualitative and quantitative sample clustering have shown that cell lines can be divided into four groups for which the most significantly different metabolites have been determined. Analysis shows that some of the major cancer metabolic markers (such as choline, lactate, and glutamine) have significantly dissimilar concentrations in different GBM groups. The obtained lists of metabolic markers for subgroups were correlated with gene expression data for the same cell lines. Metabolic analysis generally agrees with gene expression measurements, and in several cases, we have shown in detail how the metabolic results can be correlated with the analysis of gene expression. Combined gene expression and metabolomics analysis have shown differential expression of transporters of metabolic markers in these cells as well as some of the major metabolic pathways leading to accumulation of metabolites. Obtained lists of marker metabolites can be leveraged for subtype determination in glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528487      PMCID: PMC3370199          DOI: 10.1074/jbc.M111.337196

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Proton NMR chemical shifts and coupling constants for brain metabolites.

Authors:  V Govindaraju; K Young; A A Maudsley
Journal:  NMR Biomed       Date:  2000-05       Impact factor: 4.044

2.  Classification of tumour 1H NMR spectra by pattern recognition.

Authors:  S L Howells; R J Maxwell; J R Griffiths
Journal:  NMR Biomed       Date:  1992 Mar-Apr       Impact factor: 4.044

3.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

4.  Cell type-specific fingerprinting of meningioma and meningeal cells by proton nuclear magnetic resonance spectroscopy.

Authors:  C L Florian; N E Preece; K K Bhakoo; S R Williams; M D Noble
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

Review 5.  The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

Authors:  Arnab Chakravarti; Adam Dicker; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

6.  NMR in cancer: VIII. Phosphorus-31 as a nuclear probe for malignant tumors.

Authors:  K S Zaner; R Damadian
Journal:  Physiol Chem Phys       Date:  1977

7.  Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours.

Authors:  C L Florian; N E Preece; K K Bhakoo; S R Williams; M Noble
Journal:  NMR Biomed       Date:  1995-09       Impact factor: 4.044

8.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

9.  Fuzzy J-Means and VNS methods for clustering genes from microarray data.

Authors:  Nabil Belacel; Miroslava Cuperlović-Culf; Mark Laflamme; Rodney Ouellette
Journal:  Bioinformatics       Date:  2004-02-26       Impact factor: 6.937

10.  17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

Authors:  Alissa H Brandes; Christopher S Ward; Sabrina M Ronen
Journal:  Breast Cancer Res       Date:  2010-10-14       Impact factor: 6.466

View more
  29 in total

1.  Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.

Authors:  Ulf D Kahlert; Menglin Cheng; Katharina Koch; Luigi Marchionni; Xing Fan; Eric H Raabe; Jarek Maciaczyk; Kristine Glunde; Charles G Eberhart
Journal:  Int J Cancer       Date:  2015-10-13       Impact factor: 7.396

2.  Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

Authors:  Patrick-Denis St-Coeur; Julie J Poitras; Miroslava Cuperlovic-Culf; Mohamed Touaibia; Pier Morin
Journal:  J Neurooncol       Date:  2015-08-28       Impact factor: 4.130

3.  Plasma amino acids indicate glioblastoma with ATRX loss.

Authors:  Ernest Jan Bobeff; Dorota Szczesna; Michał Bieńkowski; Karolina Janczar; Malgorzata Chmielewska-Kassassir; Karol Wiśniewski; Wielisław Papierz; Lucyna Alicja Wozniak; Dariusz Jan Jaskólski
Journal:  Amino Acids       Date:  2021-01-04       Impact factor: 3.520

4.  Evaluating line-broadening factors on a reference spectrum as a bucketing method for NMR based metabolomics.

Authors:  Bo Wang; Antoniette M Maldonado-Devincci; Lin Jiang
Journal:  Anal Biochem       Date:  2020-07-29       Impact factor: 3.365

5.  Investigation of Inter- and Intratumoral Heterogeneity of Glioblastoma Using TOF-SIMS.

Authors:  Samvel K Gularyan; Alexander A Gulin; Ksenia S Anufrieva; Victoria O Shender; Michail I Shakhparonov; Soniya Bastola; Nadezhda V Antipova; Tatiana F Kovalenko; Yury P Rubtsov; Yaroslav A Latyshev; Alexander A Potapov; Marat S Pavlyukov
Journal:  Mol Cell Proteomics       Date:  2020-04-06       Impact factor: 5.911

6.  A review of applications of metabolomics in cancer.

Authors:  Richard D Beger
Journal:  Metabolites       Date:  2013-07-05

Review 7.  Glioblastoma Metabolomics-In Vitro Studies.

Authors:  Karol Jaroch; Paulina Modrakowska; Barbara Bojko
Journal:  Metabolites       Date:  2021-05-13

8.  Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide.

Authors:  Miroslava Cuperlovic-Culf; Mohamed Touaibia; Patrick-Denis St-Coeur; Julie Poitras; Pier Morin; Adrian S Culf
Journal:  Metabolites       Date:  2014-09-12

Review 9.  Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma.

Authors:  Kamran A Ahmed; Prakash Chinnaiyan
Journal:  Metabolites       Date:  2014-08-27

Review 10.  Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.

Authors:  Patrick-Denis St-Coeur; Mohamed Touaibia; Miroslava Cuperlovic-Culf; Pier Morin
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-06-01       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.